The US documents are background and supporting information, nothing too interesting.
The EU documents are just Noxopharm requesting modifications to the patent description suggested by the EU. Nothing controversial that will impact either the claims or the grant, imo.
Ann: Noxopharm Secures Key European Patent Allowance for Veyonda, page-28
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.06M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 11.5¢ | $5.653K | 48.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 22101 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 159073 | 5 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |